On November 18, Danno Pharmaceuticals announced that its world's first innovative drug TNP-2198 for the treatment of Helicobacter pylori infection successfully completed the Phase III clinical trial and reached the primary endpoint of the study, showing multiple advantages compared with the bismuth quadruple.

Dr. Ma Zhenkun, founder of Danno Pharmaceuticals, said: "TNP-2198 is the world's first new antibacterial drug developed specifically for Helicobacter pylori infection in 30 years, with a unique multi-target synergistic mechanism."

The experimental results show that the eradication rate of Helicobacter pylori with the TNP-2198 triple regimen is still over 90%, which is also higher than the bismuth quadruple regimen, which is consistent with the results of the main analysis population, indicating that the TNP-2198 triple regimen has a good eradication effect on drug-resistant infections.

TNP-2198 is a new antibacterial drug candidate with a unique multi-target synergistic mechanism. It has the advantages of overcoming antibiotic resistance, reducing the frequency of resistance and being effective against slow-metabolizing spherical bacteria. It has received support from the National 13th Five-Year Plan "Major New Drug Creation" major science and technology project. Danno Pharmaceuticals has completed 7 Phase I-III clinical trials of TNP-2198 and achieved positive results.

Danno Pharmaceuticals has the new drug clinical trial (IND) license for TNP-2198 in the United States, the US FDA qualified anti-infective product (QIDP) and Fast Track qualifications.

https://mp.weixin.qq.com/